mRNA influenza vaccine: reprogramming in 2 weeks https://ymaho.com/mrna-influenza-vaccine-reprogramming-in-2-weeks
Scientists at Vector have created an mRNA influenza vaccine that can be adapted to a new strain in 14 days. Learn how this will change vaccination. Read more!
MIT synthetic circuit reverses cellular aging https://ymaho.com/mit-synthetic-circuit-reverses-cellular-aging
MIT scientists reprogrammed cell aging without cancer risk. Learn how the genetic switch works and when to expect therapy. Read more.
Nanoparticles against immune aging: a new strategy https://ymaho.com/nanoparticles-against-immune-aging-a-new-strategy
Scientists proposed metabolic reprogramming of immune cells using nanoparticles to combat age-related aging. Learn about the prospects and limitations of the method.
Nanoparticles against immune aging: ACS Nano breakthrough https://ymaho.com/nanoparticles-against-immune-aging-acs-nano-breakthrough
Scientists propose metabolic reprogramming of immune cells using nanoparticles for immune rejuvenation and healthy longevity. Read the analysis.
Human Cell Rejuvenation Therapy Trials https://ymaho.com/human-cell-rejuvenation-therapy-trials
Learn about the first clinical trial of ER-100 cell rejuvenation therapy from Life Biosciences. How epigenetic reprogramming can reverse aging. Read details.
Sam Altman's $180M Investment in Anti-Aging via AI and Cells https://ymaho.com/sam-altman-s-180m-investment-in-anti-aging-via-ai-and-cells
Analysis of Sam Altman's investments in Retro Biosciences, GPT-4b micro AI model, and cellular reprogramming. Real prospects, risks, and competitors. Read details.
Epigenome editing of aging: results of SynBioBeta 2026 https://ymaho.com/epigenome-editing-of-aging-results-of-synbiobeta-2026
At SynBioBeta 2026, cell stability engineering was presented: AI mapping of aging and proteostasis editing for treating age-related diseases. Learn the details of the breakthrough.
Mesenchymal drift: a new mechanism of aging and Alzheimer's treatment https://ymaho.com/mesenchymal-drift-a-new-mechanism-of-aging-and-alzheimer-s-treatment
Discovery of mesenchymal drift — key to cell rejuvenation. A clinical trial for Alzheimer's disease treatment starts with 240 patients. Learn more.
Senolytic dasatinib+quercetin rejuvenated tissues by 2-3 years https://ymaho.com/senolytic-dasatinib-quercetin-rejuvenated-tissues-by-2-3-years
Senolytic drugs D+Q reduced biological age in humans for the first time. Learn how removing old cells rejuvenates the body. Read details of the breakthrough.